Mycenax Biotech (ROCO:4726) ROCE % : -11.97% (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Mycenax Biotech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Mycenax Biotech's annualized ROCE % for the quarter that ended in Dec. 2024 was -11.97%.

Mycenax Biotech ROCE % Historical Data

The historical data trend for Mycenax Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mycenax Biotech ROCE % Chart

Mycenax Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

2.30

-4.33

-13.83

-19.22

-15.36

Mycenax Biotech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-18.28	-17.14	-12.64	-18.75	-11.97

Mycenax Biotech ROCE % Calculation

Mycenax Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-439.669	/	( ( (3770.401 - 753.423)	+	(3368.376 - 661.496) )	/ 2 )
	=	-439.669	/	( (3016.978	+	2706.88)	/ 2 )
	=	-439.669	/	2861.929
	=	-15.36 %

Mycenax Biotech's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-331.676	/	( ( (3477.766 - 644.103)	+	(3368.376 - 661.496) )	/ 2 )
	=	-331.676	/	( ( 2833.663	+	2706.88 )	/ 2 )
	=	-331.676	/	2770.2715
	=	-11.97 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Mycenax Biotech (ROCO:4726) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Mycenax Biotech ROCE % Related Terms

Thank you for viewing the detailed overview of Mycenax Biotech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mycenax Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mycenax Biotech Inc (ROCO:4726) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.66, Shengyi 2nd Road, 7th Floor, Hsinchu Science Park, Hsinchu County, Zhubei, TWN, 302041

Website

https://www.mycenax.com.tw

Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards.

Mycenax Biotech Headlines

No Headlines